Carbocisteine
Based on 1 Customer Validation
Carbocisteine is an orally active mucolytic agent. Carbocisteine attenuates the phosphorylation of NF-κB p65 and ERK1/2. Carbocisteine modulates Nrf2/HO-1 and NFκB interplay. Carbocisteine inhibits Apoptosis. Carbocisteine is used in chronic obstructive pulmonary disease (COPD) research.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 638-23-3
- Formula: C5H9NO4S
- Molecular Weight:179.19
-
Storage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
NMPA-Approved Drug Library
HY-L053
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Non-natural Amino Acid Compound Library
HY-L198
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
FDA Kinase Inhibitor Library
HY-L230
-
RNA Binding Bioactive Compound Library
HY-L248
-
Lactylation Compound Library
HY-L249
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
>50 μM
Compound: 3f
|
Cytotoxic activity against HeLa cells
Cytotoxic activity against HeLa cells
|
[PMID: 17524640] |
Carbocisteine (10-1000 μM, 24 h) attenuates hydrogen peroxide-induced inflammatory injury in A549 cells via NF-κB and ERK1/2 MAPK pathways[4].
Carbocisteine (L-Carbocisteine, 10 μM, from 3 days before infection) shows inhibitory effects on type A seasonal influenza virus infection in human airway epithelial cells[5].
Carbocisteine (L-carbocisteine, 10 μM, 72 h) inhibits oxidant-induced apoptosis in cultured human airway epithelial cells[12].
Carbocisteine (10-1000 μM, 24 h) attenuates TNF-α-induced inflammation in human alveolar epithelial cells in vitro through suppressing NF-κB and ERK1/2 MAPK signaling pathways[13].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
. Carbocisteine (100 mg/kg, p.o.) promotes phagocytosis of apoptotic cells by alveolar macrophages in BALB/c mice[3].
. Carbocisteine (125-250 mg/kg/d, gavage, once a week for 3 weeks) protects against emphysema induced by cigarette smoke extract in rats[6].
Carbocisteine (500 mg/kg/day, p.o., in two divided doses, 2 days) inhibits oxidative stress, inflammatory response, and apoptosis in acetic acid-induced UC by modulating the Nrf2/HO-1 and NFκB interplay in rats[7].
Carbocisteine (112.5-225 mg/kg/d, gavage, 12 weeks) inhibits the expression of Muc5b in COPD mouse model[8].
Carbocisteine (300 mg/kg, i.g., once every day for the last 6 weeks) ameliorates steroid resistance in rat COPD model[9].
Carbocisteine (250 mg/kg ×2/day, p.o., 25 days) inhibits the changes in these enzyme (fucosidase, sialidase, fucosyltransferase and sialyltransferase) activities and the expressions of Muc5ac mRNA and protein in the lungin SO2-exposed rats[10].
Carbocysteine (300 mg/kg, p.o., every day both from week 6 to week 12 of smoke exposure) restores steroid sensitivity by targeting histone deacetylase 2 in a thiol/GSH-dependent manner in rats[11].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 638-23-3
-
Appearance Solid
-
Molecular Weight 179.19
-
Formula C5H9NO4S
-
Color White to off-white
-
SMILES
N[C@@H](CSCC(O)=O)C(O)=O
-
Synonyms
Carbocysteine
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
H2O : 2 mg/mL (11.16 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (11.16 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Paola Rogliani, et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019 May 27;20(1):104. [Content Brief]
[2]. Yageta Y, et al. Carbocisteine reduces virus-induced pulmonary inflammation in mice exposed to cigarette smoke. Am J Respir Cell Mol Biol. 2014 May;50(5):963-73. [Content Brief]
[3]. Inoue M, et al. Carbocisteine promotes phagocytosis of apoptotic cells by alveolar macrophages. Eur J Pharmacol. 2012 Feb 29;677(1-3):173-9. [Content Brief]
[4]. Wang W, et al. Carbocisteine attenuates hydrogen peroxide-induced inflammatory injury in A549 cells via NF-κB and ERK1/2 MAPK pathways. Int Immunopharmacol. 2015 Feb;24(2):306-313. [Content Brief]
[5]. Yamaya M, et al. Inhibitory effects of carbocisteine on type A seasonal influenza virus infection in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2010 Aug;299(2):L160-8. [Content Brief]
[6]. Hanaoka M, et al. Carbocisteine protects against emphysema induced by cigarette smoke extract in rats. Chest. 2011 May;139(5):1101-1108. [Content Brief]
[7]. Abdelhamid AM, et al. Carbocisteine as a Modulator of Nrf2/HO-1 and NFκB Interplay in Rats: New Inspiration for the Revival of an Old Drug for Treating Ulcerative Colitis. Front Pharmacol. 2022 Jun 8;13:887233. [Content Brief]
[8]. Song Y, et al. Carbocisteine inhibits the expression of Muc5b in COPD mouse model. Drug Des Devel Ther. 2019 Sep 16;13:3259-3268. [Content Brief]
[9]. Song Y, et al. A mucoactive drug carbocisteine ameliorates steroid resistance in rat COPD model. Pulm Pharmacol Ther. 2016 Aug;39:38-47. [Content Brief]
[10]. Ishibashi Y, et al. Effects of carbocisteine on altered activities of glycosidase and glycosyltransferase and expression of Muc5ac in SO2-exposed rats. Eur J Pharmacol. 2004 Mar 8;487(1-3):7-15. [Content Brief]
[11]. Song Y, et al. Carbocysteine restores steroid sensitivity by targeting histone deacetylase 2 in a thiol/GSH-dependent manner. Pharmacol Res. 2015 Jan;91:88-98. [Content Brief]
[12]. Yoshida M, et al. Carbocisteine inhibits oxidant-induced apoptosis in cultured human airway epithelial cells. Respirology. 2009 Sep;14(7):1027-34. [Content Brief]
[13]. Wang W, et al. Carbocisteine attenuates TNF-α-induced inflammation in human alveolar epithelial cells in vitro through suppressing NF-κB and ERK1/2 MAPK signaling pathways. Acta Pharmacol Sin. 2016 May;37(5):629-36. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 5.5807 mL | 27.9033 mL | 55.8067 mL | 139.5167 mL |
| 5 mM | 1.1161 mL | 5.5807 mL | 11.1613 mL | 27.9033 mL | |
| 10 mM | 0.5581 mL | 2.7903 mL | 5.5807 mL | 13.9517 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Carbocisteine Related Classifications
HY-D0205A Related Classifications
Powered by Bioz